Financière de Tubize SA (TUB.BR)
EUR 116.4
(0.52%)
EUR 116.4
(0.52%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 88.15 Million EUR | -49.4% |
| 2022 | 174.22 Million EUR | -54.16% |
| 2021 | 380.09 Million EUR | 45.9% |
| 2020 | 260.51 Million EUR | 23891.69% |
| 2019 | -1.09 Million EUR | -100.38% |
| 2018 | 285.15 Million EUR | -0.27% |
| 2017 | 285.93 Million EUR | 57.81% |
| 2016 | 181.18 Million EUR | -14.75% |
| 2015 | 212.52 Million EUR | 249.29% |
| 2014 | 60.84 Million EUR | -1.4% |
| 2013 | 61.7 Million EUR | -20.7% |
| 2012 | 77.81 Million EUR | 20.29% |
| 2011 | 64.68 Million EUR | 209.97% |
| 2010 | 20.86 Million EUR | -87.22% |
| 2009 | 163.3 Million EUR | 18145.08% |
| 2008 | -905 Thousand EUR | -102.29% |
| 2007 | 39.53 Million EUR | -91.72% |
| 2006 | 477.27 Million EUR | 62.42% |
| 2005 | 293.85 Million EUR | 137.16% |
| 2004 | 123.9 Million EUR | 4.92% |
| 2003 | 118.09 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 92.93 Million EUR | 0.0% |
| 2023 Q4 | -2.91 Million EUR | 0.0% |
| 2023 Q2 | 91.06 Million EUR | 0.0% |
| 2023 FY | 88.15 Million EUR | -49.4% |
| 2022 FY | 174.22 Million EUR | -54.16% |
| 2022 Q2 | 144.47 Million EUR | 0.0% |
| 2022 Q4 | -59.3 Million EUR | 0.0% |
| 2021 Q2 | 204.82 Million EUR | 0.0% |
| 2021 FY | 380.09 Million EUR | 45.9% |
| 2021 Q4 | 175.26 Million EUR | 0.0% |
| 2020 Q4 | 130.85 Million EUR | 0.0% |
| 2020 FY | 260.51 Million EUR | 23891.69% |
| 2020 Q2 | 129.66 Million EUR | 0.0% |
| 2019 FY | -1.09 Million EUR | -100.38% |
| 2019 Q2 | 147.16 Million EUR | 0.0% |
| 2019 Q4 | 44.51 Million EUR | 0.0% |
| 2018 FY | 285.15 Million EUR | -0.27% |
| 2018 Q1 | 143.4 Million EUR | 8.71% |
| 2018 Q4 | 87.63 Million EUR | 0.0% |
| 2018 Q2 | 197.51 Million EUR | 37.73% |
| 2017 Q2 | 154.01 Million EUR | 115.46% |
| 2017 FY | 285.93 Million EUR | 57.81% |
| 2017 Q4 | 131.91 Million EUR | 0.0% |
| 2017 Q1 | 71.48 Million EUR | -4.47% |
| 2016 FY | 181.18 Million EUR | -14.75% |
| 2016 Q4 | 74.83 Million EUR | 0.0% |
| 2016 Q2 | 106.35 Million EUR | 134.8% |
| 2016 Q1 | 45.29 Million EUR | -63.14% |
| 2015 FY | 212.52 Million EUR | 249.29% |
| 2015 Q3 | 53.13 Million EUR | -40.72% |
| 2015 Q4 | 122.89 Million EUR | 131.3% |
| 2015 Q2 | 89.63 Million EUR | 68.7% |
| 2015 Q1 | 53.13 Million EUR | 173.93% |
| 2014 Q4 | 19.39 Million EUR | 27.51% |
| 2014 FY | 60.84 Million EUR | -1.4% |
| 2014 Q3 | 15.21 Million EUR | -63.3% |
| 2014 Q1 | 15.21 Million EUR | -48.64% |
| 2014 Q2 | 41.44 Million EUR | 172.49% |
| 2013 Q2 | 14.8 Million EUR | -4.05% |
| 2013 Q1 | 15.42 Million EUR | 0.0% |
| 2013 Q4 | 29.61 Million EUR | 91.98% |
| 2013 Q3 | 15.42 Million EUR | 4.22% |
| 2013 FY | 61.7 Million EUR | -20.7% |
| 2012 Q1 | 19.45 Million EUR | 0.0% |
| 2012 FY | 77.81 Million EUR | 20.29% |
| 2012 Q3 | 19.45 Million EUR | 0.0% |
| 2012 Q4 | 15.42 Million EUR | -20.7% |
| 2012 Q2 | 19.45 Million EUR | 0.0% |
| 2011 Q3 | 16.17 Million EUR | 0.0% |
| 2011 FY | 64.68 Million EUR | 209.97% |
| 2011 Q4 | 19.45 Million EUR | 20.29% |
| 2011 Q2 | 16.17 Million EUR | 0.0% |
| 2011 Q1 | 16.17 Million EUR | 0.0% |
| 2010 Q4 | 16.17 Million EUR | 209.97% |
| 2010 Q1 | 5.21 Million EUR | 0.0% |
| 2010 FY | 20.86 Million EUR | -87.22% |
| 2010 Q3 | 5.21 Million EUR | 0.0% |
| 2010 Q2 | 5.21 Million EUR | 0.0% |
| 2009 Q4 | 5.21 Million EUR | -87.22% |
| 2009 Q1 | 40.82 Million EUR | 0.0% |
| 2009 Q2 | 40.82 Million EUR | 0.0% |
| 2009 FY | 163.3 Million EUR | 18145.08% |
| 2009 Q3 | 40.82 Million EUR | 0.0% |
| 2008 Q1 | -226.25 Thousand EUR | 0.0% |
| 2008 Q3 | -226.25 Thousand EUR | 0.0% |
| 2008 Q2 | -226.25 Thousand EUR | 0.0% |
| 2008 Q4 | 40.82 Million EUR | 18145.08% |
| 2008 FY | -905 Thousand EUR | -102.29% |
| 2007 Q2 | 9.88 Million EUR | 0.0% |
| 2007 Q4 | -226.25 Thousand EUR | -102.29% |
| 2007 Q1 | 9.88 Million EUR | 0.0% |
| 2007 Q3 | 9.88 Million EUR | 0.0% |
| 2007 FY | 39.53 Million EUR | -91.72% |
| 2006 Q1 | 119.31 Million EUR | 0.0% |
| 2006 Q2 | 119.31 Million EUR | 0.0% |
| 2006 Q3 | 119.31 Million EUR | 0.0% |
| 2006 Q4 | 9.88 Million EUR | -91.72% |
| 2006 FY | 477.27 Million EUR | 62.42% |
| 2005 FY | 293.85 Million EUR | 137.16% |
| 2005 Q4 | 119.31 Million EUR | 62.42% |
| 2005 Q3 | 73.46 Million EUR | 0.0% |
| 2005 Q2 | 73.46 Million EUR | 0.0% |
| 2005 Q1 | 73.46 Million EUR | 0.0% |
| 2004 Q4 | 73.46 Million EUR | 137.16% |
| 2004 Q2 | 30.97 Million EUR | 0.0% |
| 2004 Q3 | 30.97 Million EUR | 0.0% |
| 2004 Q1 | 30.97 Million EUR | 0.0% |
| 2004 FY | 123.9 Million EUR | 4.92% |
| 2003 Q3 | 29.52 Million EUR | 0.0% |
| 2003 FY | 118.09 Million EUR | 0.0% |
| 2003 Q2 | 29.52 Million EUR | 0.0% |
| 2003 Q1 | 29.52 Million EUR | 0.0% |
| 2003 Q4 | 30.97 Million EUR | 4.92% |
| 2002 Q4 | 29.52 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nicox S.A. | -20.88 Million EUR | 522.16% |
| European Medical Solutions | -709 Thousand EUR | 12533.183% |
| FERMENTALG | -14.14 Million EUR | 723.065% |
| argenx SE | -272.91 Million EUR | 132.3% |
| BioSenic S.A. | -28.77 Million EUR | 406.315% |
| Celyad Oncology SA | -8.44 Million EUR | 1143.457% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 673.155% |
| Onward Medical N.V. | -36.18 Million EUR | 343.64% |
| Oxurion NV | -18.96 Million EUR | 564.712% |
| PHAXIAM Therapeutics S.A. | -23.48 Million EUR | 475.303% |
| UCB SA | 343 Million EUR | 74.3% |